Targeting smokers at increased risk for relapse: Treating women and those with a history of depression

Stevens S. Smith, Douglas E. Jorenby, Scott J. Leischow, Mitchell A. Nides, Stephen I. Rennard, J. Andrew Johnston, Brenda Jamerson, Michael C. Fiore, Timothy B. Baker

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Some studies have shown that female smokers and smokers with a history of depression have an increased risk of relapse following smoking cessation treatment. This study examined the efficacy of bupropion sustained-release (SR) and the nicotine patch for smoking cessation in subgroups of smokers at possible risk for relapse. Data for this study were from a previously published randomized, double-blind, placebo-controlled clinical trial in which 893 smokers were randomized to four treatment conditions: placebo tablet+placebo patch, placebo tablet+21 mg/24-hr nicotine patch, 300 mg bupropion SR+placebo patch, and 300 mg bupropion SR+21 mg/24-hr nicotine patch. Study medication continued for 8 weeks after the quit day; brief individual cessation counseling was provided during weekly clinic visits. In comparison to the placebo tablet, bupropion SR approximately tripled 1-year non-smoking rates among women and previously depressed individuals. In contrast, the nicotine patch did not significantly improve cessation rates for any group. We conclude that bupropion SR is a first-line treatment for smoking that has the potential to benefit all smokers, especially women and the previously depressed.

Original languageEnglish (US)
Pages (from-to)99-109
Number of pages11
JournalNicotine and Tobacco Research
Volume5
Issue number1
DOIs
StatePublished - Feb 2003
Externally publishedYes

Fingerprint

Bupropion
Tobacco Use Cessation Products
Placebos
Depression
Recurrence
Tablets
Smoking Cessation
Withholding Treatment
Controlled Clinical Trials
Ambulatory Care
Counseling
Smoking
Therapeutics

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Smith, S. S., Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., ... Baker, T. B. (2003). Targeting smokers at increased risk for relapse: Treating women and those with a history of depression. Nicotine and Tobacco Research, 5(1), 99-109. https://doi.org/10.1080/14622200307263

Targeting smokers at increased risk for relapse : Treating women and those with a history of depression. / Smith, Stevens S.; Jorenby, Douglas E.; Leischow, Scott J.; Nides, Mitchell A.; Rennard, Stephen I.; Johnston, J. Andrew; Jamerson, Brenda; Fiore, Michael C.; Baker, Timothy B.

In: Nicotine and Tobacco Research, Vol. 5, No. 1, 02.2003, p. 99-109.

Research output: Contribution to journalArticle

Smith, SS, Jorenby, DE, Leischow, SJ, Nides, MA, Rennard, SI, Johnston, JA, Jamerson, B, Fiore, MC & Baker, TB 2003, 'Targeting smokers at increased risk for relapse: Treating women and those with a history of depression', Nicotine and Tobacco Research, vol. 5, no. 1, pp. 99-109. https://doi.org/10.1080/14622200307263
Smith, Stevens S. ; Jorenby, Douglas E. ; Leischow, Scott J. ; Nides, Mitchell A. ; Rennard, Stephen I. ; Johnston, J. Andrew ; Jamerson, Brenda ; Fiore, Michael C. ; Baker, Timothy B. / Targeting smokers at increased risk for relapse : Treating women and those with a history of depression. In: Nicotine and Tobacco Research. 2003 ; Vol. 5, No. 1. pp. 99-109.
@article{3fbcbd44ce6f4e25b2275e078cd6b697,
title = "Targeting smokers at increased risk for relapse: Treating women and those with a history of depression",
abstract = "Some studies have shown that female smokers and smokers with a history of depression have an increased risk of relapse following smoking cessation treatment. This study examined the efficacy of bupropion sustained-release (SR) and the nicotine patch for smoking cessation in subgroups of smokers at possible risk for relapse. Data for this study were from a previously published randomized, double-blind, placebo-controlled clinical trial in which 893 smokers were randomized to four treatment conditions: placebo tablet+placebo patch, placebo tablet+21 mg/24-hr nicotine patch, 300 mg bupropion SR+placebo patch, and 300 mg bupropion SR+21 mg/24-hr nicotine patch. Study medication continued for 8 weeks after the quit day; brief individual cessation counseling was provided during weekly clinic visits. In comparison to the placebo tablet, bupropion SR approximately tripled 1-year non-smoking rates among women and previously depressed individuals. In contrast, the nicotine patch did not significantly improve cessation rates for any group. We conclude that bupropion SR is a first-line treatment for smoking that has the potential to benefit all smokers, especially women and the previously depressed.",
author = "Smith, {Stevens S.} and Jorenby, {Douglas E.} and Leischow, {Scott J.} and Nides, {Mitchell A.} and Rennard, {Stephen I.} and Johnston, {J. Andrew} and Brenda Jamerson and Fiore, {Michael C.} and Baker, {Timothy B.}",
year = "2003",
month = "2",
doi = "10.1080/14622200307263",
language = "English (US)",
volume = "5",
pages = "99--109",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Targeting smokers at increased risk for relapse

T2 - Treating women and those with a history of depression

AU - Smith, Stevens S.

AU - Jorenby, Douglas E.

AU - Leischow, Scott J.

AU - Nides, Mitchell A.

AU - Rennard, Stephen I.

AU - Johnston, J. Andrew

AU - Jamerson, Brenda

AU - Fiore, Michael C.

AU - Baker, Timothy B.

PY - 2003/2

Y1 - 2003/2

N2 - Some studies have shown that female smokers and smokers with a history of depression have an increased risk of relapse following smoking cessation treatment. This study examined the efficacy of bupropion sustained-release (SR) and the nicotine patch for smoking cessation in subgroups of smokers at possible risk for relapse. Data for this study were from a previously published randomized, double-blind, placebo-controlled clinical trial in which 893 smokers were randomized to four treatment conditions: placebo tablet+placebo patch, placebo tablet+21 mg/24-hr nicotine patch, 300 mg bupropion SR+placebo patch, and 300 mg bupropion SR+21 mg/24-hr nicotine patch. Study medication continued for 8 weeks after the quit day; brief individual cessation counseling was provided during weekly clinic visits. In comparison to the placebo tablet, bupropion SR approximately tripled 1-year non-smoking rates among women and previously depressed individuals. In contrast, the nicotine patch did not significantly improve cessation rates for any group. We conclude that bupropion SR is a first-line treatment for smoking that has the potential to benefit all smokers, especially women and the previously depressed.

AB - Some studies have shown that female smokers and smokers with a history of depression have an increased risk of relapse following smoking cessation treatment. This study examined the efficacy of bupropion sustained-release (SR) and the nicotine patch for smoking cessation in subgroups of smokers at possible risk for relapse. Data for this study were from a previously published randomized, double-blind, placebo-controlled clinical trial in which 893 smokers were randomized to four treatment conditions: placebo tablet+placebo patch, placebo tablet+21 mg/24-hr nicotine patch, 300 mg bupropion SR+placebo patch, and 300 mg bupropion SR+21 mg/24-hr nicotine patch. Study medication continued for 8 weeks after the quit day; brief individual cessation counseling was provided during weekly clinic visits. In comparison to the placebo tablet, bupropion SR approximately tripled 1-year non-smoking rates among women and previously depressed individuals. In contrast, the nicotine patch did not significantly improve cessation rates for any group. We conclude that bupropion SR is a first-line treatment for smoking that has the potential to benefit all smokers, especially women and the previously depressed.

UR - http://www.scopus.com/inward/record.url?scp=0037291455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037291455&partnerID=8YFLogxK

U2 - 10.1080/14622200307263

DO - 10.1080/14622200307263

M3 - Article

C2 - 12745511

AN - SCOPUS:0037291455

VL - 5

SP - 99

EP - 109

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 1

ER -